Tag results:
Industry & Policy News
Newsletters
Call for Type 1 Diabetes Screening Gains Momentum
[University of Colorado] The approval of approval of Tzield (teplizumab) in November of 2022, the first-ever disease-modifying drug for T1D, boosted screening momentum. The BDC led clinical trials on the drug, which offers the first tangible reason for testing for the disease that halts glucose-regulating insulin production. In April, Simmons and her University of Colorado School Medicine colleagues became the first in the state to treat a clinical patient with the novel drug on the CU Anschutz Medical Campus.
ESC & iPSC News
IICD Faculty Members Named 2023 Allen Distinguished Investigators
[Columbia University] Two IICD faculty members, Elham Azizi - Herbert and Florence Irving Assistant Professor of Cancer Data Research and Assistant Professor of Biomedical Engineering - and José McFaline-Figueroa - Assistant Professor of Biomedical Engineering -, are among the 18 new Allen Distinguished Investigators.
Neural Cell News
Scientists at King’s College London and bit.bio Collaborate to Develop Multi-Cell Models of the Human Brain With Optimised Open-Source Protocols for Use by Any...
[bit.bio (BusinessWire, Inc.)] bit.bio, the company coding human cells for novel cures, and the Institute of Psychiatry, Psychology & Neuroscience at King’s College London today announce a collaboration to build multi-cell models of the human brain using bit.bio’s ioCells™️.
Cell Therapy News
Most Clinical Trials Run in Canada Failed to Take Basic Steps Toward Transparency, Analysis Finds
[STAT News] Just 3% of more than 3,700 studies run exclusively in Canada over a recent 10-year period were registered prospectively, reported results, and published the findings, underscoring ongoing concerns about clinical trial transparency, according to a new analysis.
Hematopoiesis News
MorphoSys, after Saying AbbVie ‘Failed,’ Defends Own Mixed Blood Cancer Data, Plots Approval Filings
[FierceBiotech] The data come from a Phase III clinical trial of pelabresib, a BET inhibitor that MorphoSys acquired in its $1.7 billion acquisition of Constellation Pharmaceuticals.
Muscle Cell News
Foundation Announces $500,000 In New Research Grants
[THE MARFAN FOUNDATION] The Marfan Foundation awarded five new two-year research grants include two Innovator Awards and three Victor McKusick Fellowship Awards. The research projects focus on aortic dissection and thoracic aortic aneurysms.